Clover Biopharmaceuticals Company Description

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally.

The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia.

It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.

In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People’s Republic of China.

Clover Biopharmaceuticals, Ltd.

Country	Cayman Islands
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	300
CEO	Joshua G. Liang

Contact Details

Address: No. 758 West Nanjing Road Shanghai China
Phone	86 40 0883 3405
Website	cloverbiopharma.com

Stock Details

Ticker Symbol	2197
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG2280A1076
SIC Code	2836

Key Executives

Name	Position
Joshua G. Liang	Chief Executive Officer and Executive Director
Dr. Yang Li Ph.D.	Chief Technology Officer
Htay Htay Han MBBS	Chief Medical Officer of Vaccine
Dr. Berry Michael Ph.D.	Chief Technical Operation Officer
Tracy Wang	Senior Vice President of Head of Regulatory Affairs, China
Dr. Nicholas Jackson M.Sc., Ph.D.	President of Global Research and Development
LiongHo Chua	President of Greater China
Dr. Igor Smolenov M.D., Ph.D.	Executive Vice President of Global Clinical Development Vaccines
Nicolas Burdin Ph.D.	Global Head of Research & Development
Francois Verdier Ph.D.	Head of Global Regulatory Affairs